Bibliography
in Personalised cancer medicine

Bibliography

Abelson, J. , and Collins, P. A. (2009). Media hyping and the ‘Herceptin access story’: an analysis of Canadian and UK newspaper coverage. Healthcare Policy, 4(3): e113.

Abraham, J. (1995). Science, politics and the pharmaceutical industry: controversy and bias in drug regulation. London: UCL Press.

Abraham, J. (2009). Partial progress: governing the pharmaceutical industry and the NHS, 1948–2008. Journal of Health Politics, Policy and Law, 34(6): 931–77.

Adam, B. , and Groves, C. (2007). Future matters: action, knowledge, ethics. Leiden: Brill.

Adam, B. , and Groves, C. (2011). Futures tended: care and future-oriented responsibility. Bulletin of Science, Technology & Society, 31(1): 17–27.

Adams, V. , Murphy, M. , and Clarke, A. (2009). Anticipation: technoscience, life, affect, temporality. Subjectivity, 28: 246–65.

Ali-Khan, S. E. , Black, L. , Palmour, N. , Hallett, M. T. , and Avard, D. (2015). Socio-ethical issues in personalized medicine: a systematic review of English language health technology assessments of gene expression profiling tests for breast cancer prognosis. International Journal of Technology Assessment in Health Care, 31(1–2): 36–50.

Allen, D. (2014). The invisible work of nurses: hospitals, organisation and healthcare. Abingdon: Routledge.

Allen, D. , and Hughes, D. (2017). Nursing and the division of labour in healthcare. Basingstoke: Macmillan International Higher Education.

All Party Parliamentary Group on Cancer (2009). Report of the All Party Parliamentary Group on Cancer's Inquiry into Inequalities in Cancer (MacMillan Cancer Support). London: All Party Parliamentary Group on Cancer.

Arnold, M. , Rutherford, M. J. , Bardot, A. , Ferlay, J. , Andersson, T. M. L. , Myklebust, T. A. , Tervonen, H. , et al. (2019). Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. The Lancet Oncology, 20(11): 1493–505.

Arribas-Ayllon, M. , Sarangi, S. , and Clarke, A. (2011). Promissory accounts of personalisation in the commercialisation of genomic knowledge. Communication & Medicine, 8(1): 53–66.

Beaudevin, C. , Peerbaye, A. , and Bourgain, C. (2019). ‘It has to become true genetics’: tumour genetics and the division of diagnostic labour in the clinic. Sociology of Health & Illness, 41(4): 643–57.

Bekelman, J. E. , and Joffe, S. (2018). Three steps toward a more sustainable path for targeted cancer drugs. JAMA, 319(21): 2167–8. doi:10.1001/jama.2018.3414 .

Bell, K. (2009). ‘If it almost kills you that means it's working!’ Cultural models of chemotherapy expressed in a cancer support group. Social Science & Medicine, 68(1): 169–76.

Bell, K. (2013). Biomarkers, the molecular gaze and the transformation of cancer survivorship. BioSocieties, 8(2): 124–43.

Bell, K. , and Kazanjian, A. (2011). PSA testing: molecular technologies and men's experience of prostate cancer survivorship. Health, Risk & Society, 13(2): 183–98.

Benjamin, R. (2014). Race for cures: rethinking the racial logics of ‘trust’ in biomedicine. Sociology Compass, 8(6): 755–69.

Benjamin, R. (2016). Informed refusal: toward a justice-based bioethics. Science, Technology, & Human Values, 41(6): 967–90.

Bickers, B. , and Aukim-Hastie, C. (2009). New molecular biomarkers for the prognosis and management of prostate cancer – the post PSA era. Anticancer Research, 29(8): 3289–98.

Birch, K. (2017). Rethinking value in the bioeconomy: finance, assetization, and the management of value. Science, Technology, & Human Values, 42(3): 460–90.

Bodkin, H. (2018). Personalised medicine ‘transforms’ survival chances in incurable cancer. The Telegraph, 6 June, www.telegraph.co.uk/science/2018/06/05/personalised-medicine-transforms-survival-chances-incurable/ (accessed 8 July 2019).

Borad, M. J. , and LoRusso, P. M. (2017). Twenty-first century precision medicine in oncology: genomic profiling in patients with cancer. Mayo Clinic Proceedings, 92(10): 1583–91.

Borup, M. , Brown, N. , Konrad, K. , and Van Lente, H. (2006). The sociology of expectations in science and technology. Technology Analysis & Strategic Management, 18(3–4): 285–98.

Boseley, S. (2013). New breast cancer test could spare women chemotherapy. The Guardian, 26 September, https://www.theguardian.com/society/2013/sep/25/women-breast-cancer-test-spares-chemotherapy (accessed 20 June 2020).

Bourret, P. , Keating, P. , and Cambrosio, A. (2011). Regulating diagnosis in post-genomic medicine: re-aligning clinical judgement? Social Science & Medicine, 73(6): 816–24.

Braun, K. , Moore, A. , Herrmann, S. L. , and Könninger, S. (2010). Science governance and the politics of proper talk: governmental bioethics as a new technology of reflexive government. Economy and Society, 39(4): 510–33.

Breast Cancer Now (2018). Breast Cancer Now responds to NICE decision to not to recommend use of tumour profiling tests. https://breastcancernow.org/news-and-blogs/news/nice-decide-not-to-recommend-use-of-tumour-profiling-tests (accessed 5 March 2018).

Brown, N. , and Michael, M. (2003). A sociology of expectations: retrospecting prospects and prospecting retrospects. Technology Analysis & Strategic Management, 15(1): 3–18.

Brown, N. , and Rappert, B. (2017). Contested futures: a sociology of prospective techno-science. Abingdon: Routledge.

Brown, P. , and de Graaf, S. (2013). Considering a future which may not exist: the construction of time and expectations amidst advanced-stage cancer. Health, Risk & Society, 15(6–7): 543–60.

Brown, P. , de Graaf, S. , Hillen, M. , Smets, E. , and van Laarhoven, H. (2015). The interweaving of pharmaceutical and medical expectations as dynamics of micro-pharmaceuticalisation: advanced-stage cancer patients’ hope in medicines alongside trust in professionals. Social Science & Medicine, 131: 313–21.

Brown, P. , Hashem, F. , and Calnan, M. (2016). Trust, regulatory processes and NICE decision-making: appraising cost-effectiveness models through appraising people and systems. Social Studies of Science, 46(1): 87–111.

Busfield, J. (2006). Pills, power, people: sociological understandings of the pharmaceutical industry. Sociology, 40(2): 297–314.

Callon, M. , and Rabeharisoa, V. (2008). The growing engagement of emergent concerned groups in political and economic life: lessons from the French Association of Neuromuscular Disease Patients. Science, Technology and Human Values, 33: 230–61.

Cambrosio, A. , Campbell, J. , Keating, P. , and Bourret, P. (2019). Multi-polar scripts: techno-regulatory environments and the rise of precision oncology diagnostic tests. Social Science & Medicine [online only/early view], 21 May 2019, 112317. https://doi.org/10.1016/j.socscimed.2019.05.022 .

Cambrosio, A. , Keating, P. , Vignola-Gagné, E. , Besle, S. , and Bourret, P. (2018). Extending experimentation: oncology's fading boundary between research and care. New Genetics and Society, 37(3): 207–26.

Cancer Research UK (2014). Breast cancer survival statistics [online]. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/survival (accessed 31 May 2019).

Chapple, A. , Ziebland, S. , and McPherson, A. (2004). Stigma, shame, and blame experienced by patients with lung cancer: qualitative study. British Medical Journal, 328(7454): 1470.

Chattoo, S. , and Ahmad, W. I. U. (2003). The meaning of cancer: illness, biography and identity. In D. Kelleher and G. Leavey (eds), Identity and Health, 19–36. Abingdon: Routledge.

Clark, A. E. , et al. (2003). Biomedicalization: technoscientific transformations of health, illness, and US biomedicine. American Sociological Review, 68(2): 161–94.

Cool, A. (2016). Detaching data from the state: biobanking and building big data in Sweden. BioSocieties, 11(3): 277–95.

Cooper, M. (2008). Life as surplus: biotechnics and the transformations of capital. Seattle, WA: Washington University Press.

Cooper, M. , and Waldby, C. (2014). Clinical labor: tissue donors and research subjects in the global bioeconomy. Durham, NC: Duke University Press.

Corrigan, O. (2003). Empty ethics: the problem with informed consent. Sociology of Health & Illness, 25(7): 768–92.

Dabbs, D. J. , Clark, B. Z. , Serdy, K. , Onisko, A. , Brufsky, A. M. , Smalley, S. , Perkins, S. and Bhargava, R. (2018). Pathologist's health-care value in the triage of Oncotype DX® testing: a value-based pathology study of tumour biology with outcomes. Histopathology, 73(4): 692–700.

Davis, C. (2015). Drugs, cancer and end-of-life care: a case study of pharmaceuticalization? Social Science & Medicine, 131: 207–14.

Davis, C. , and Abraham, J. (2013). Unhealthy pharmaceutical regulation: innovation, politics and promissory science. Basingstoke: Palgrave Macmillan.

Davies, S. C. (2017). Annual Report of the Chief Medical Officer 2016, Generation Genome. London: Department of Health.

Davies, M. , and Sque, M. (2002). Living on the outside looking in: a theory of living with advanced breast cancer. International Journal of Palliative Nursing, 8(12): 583–90.

de Freitas, C. , and Martin, G. (2015). Inclusive public participation in health: policy, practice and theoretical contributions to promote the involvement of marginalised groups in healthcare. Social Science and Medicine, 135: 31–9.

Degeling, C. , Carter, S. M. , and Rychetnik, L. (2015). Which public and why deliberate? A scoping review of public deliberation in public health and health policy research. Social Science & Medicine, 131: 114–21.

Derks, M. G. , and van de Velde, C. J. (2018). Neoadjuvant chemotherapy in breast cancer: more than just downsizing. The Lancet Oncology, 19(1): 2–3.

DeVita, V. T. , and Chu, E. (2008). A history of cancer chemotherapy. Cancer Research, 68(21): 8643–53.

Dheensa, S. , Samuel, G. , Lucassen, A. M. , and Farsides, B. (2018). Towards a national genomics medicine service: the challenges facing clinical-research hybrid practices and the case of the 100,000 genomes project. Journal of Medical Ethics, 44(6): 397–403.

Dixon-Woods, M. , Ashcroft, R. E. , Jackson, C. J. , Tobin, M. D. , Kivits, J. , Burton, P. R. , and Samani, N. J. (2007). Beyond ‘misunderstanding’: written information and decisions about taking part in a genetic epidemiology study. Social Science & Medicine, 65(11): 2212–22.

Dixon-Woods, M. , and Tarrant, C. (2009). Why do people cooperate with medical research? Findings from three studies. Social Science & Medicine, 68(12): 2215–22.

Dowsett, M. , and Dunbier, A. K. (2008). Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clinical Cancer Research, 14(24): 8019–26.

Dussauge, I. , Claes-Fredrik, H. , and Francis, L. (eds) (2015). Value practices in the life sciences and medicine. Oxford: Oxford University Press.

Ebeling, M. F. E. (2016). Healthcare and big data: digital spectres and phantom objects. Basingstoke: Palgrave.

Ehlers, N. , and Krupar, S. (2014). Hope logics: biomedicine, affective conventions of cancer, and the governing of biocitizenry. Configurations, 22(3): 385–413.

Ehrenreich, B. (2001). Welcome to Cancerland: a mammogram leads to a cult of pink kitsch. Harper's Magazine, November, 43–53.

Felt, U. , and Fochler, M. (2010). Machineries for making publics: inscribing and de-scribing publics in public engagement. Minerva, 48(3): 219–38.

Fojo, T. , Mailankody, S. , and Lo, A. (2014). Unintended consequences of expensive cancer therapeutics – the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity. JAMA Otolaryngology: Head & Neck Surgery, 140(12): 1225–36. doi:10.1001/jamaoto.1570 .

Fortun, M. (2008). Promising genomics: Iceland and deCODE genetics in a world of speculation. Berkeley, CA: University of California Press.

Frank, A. (2003). Survivorship as craft and conviction: reflections on research in progress. Qualitative Health Research, 13(2): 247–55.

Fujimura, J. H. (1996). Crafting science: a sociohistory of the quest for the genetics of cancer. Cambridge, MA: Harvard University Press.

Gabe, J. , Chamberlain, K. , Norris, P. , Dew, K. , Madden, H. , and Hodgetts, D. (2012). The debate about the funding of Herceptin: a case study of ‘countervailing powers’. Social Science & Medicine, 75(12): 2353–61.

Gallagher, J. (2018). Breast cancer: test means fewer women will need chemotherapy [online]. www.bbc.co.uk/news/health-44347381 (accessed 5 March 2019).

Gardner, J. , Samuel, G. , and Williams, C. (2015). Sociology of low expectations: recalibration as innovation work in biomedicine. Science, Technology, & Human Values, 40(6): 998–1021.

Gavan, S. P. , Thompson, A. J. , and Payne, K. (2018). The economic case for precision medicine. Expert Review of Precision Medicine and Drug Development, 3(1): 1–9.

Gerlitz, C. , and Helmond, A. (2013). The like economy: social buttons and the data-intensive web. New Media & Society, 15(8): 1348–65.

Gillespie., C. (2012). The experience of risk as ‘measured vulnerability’: health screening and lay uses of numerical risk. Sociology of Health & Illness, 34(2): 194–207.

Good, M. J. D. (2001). The biotechnical embrace. Culture, Medicine and Psychiatry, 25(4): 395–410.

Good, M. J. D. , Good, B. J. , Schaffer, C. , and Lind, S. E. (1990). American oncology and the discourse on hope. Culture, Medicine and Psychiatry, 14(1): 59–79.

Goven, J. , and Pavone, V. (2015). The bioeconomy as political project: a Polanyian analysis. Science, Technology, & Human Values, 40(3): 302–37.

Greenhalgh, T. (2009). Patient and public involvement in chronic illness: beyond the expert patient. British Medical Journal, 338: b49.

Guy, M. (2019). Between ‘going private’ and ‘NHS privatisation’: patient choice, competition reforms and the relationship between the NHS and private healthcare in England. Legal Studies, 39(3): 479–98.

Haase, R. , Michie, M. , and Skinner, D. (2015). Flexible positions, managed hopes: the promissory bioeconomy of a whole genome sequencing cancer study. Social Science & Medicine, 130: 146–53.

Hall, S. , Massey, D. , and Rustin, M. (2014). After neoliberalism: analysing the present. In S. Hall, D. Massey and M. Rustin (eds), After neoliberalism? The Kilburn manifesto, 8–22. London: Lawrence & Wishart.

Ham, C. , Baird, B. , Gregory, S. , Jabbal, J. , and Alderwick, H. (2015). The NHS under the coalition government. Part one: NHS reform. London: The King's Fund. https://www.kingsfund.org.uk/sites/default/files/field/field_publication_file/the-nhs-under-the-coalition-government-part-one-nhs-reform.pdf (accessed 20 June 2020).

Hamilton, A. B. (1999). Psychological aspects of ovarian cancer. Cancer Investigation, 17(5): 335–41.

Hamilton, C. (2008). Intellectual property rights, the bioeconomy and the challenge of biopiracy. Genomics, Society and Policy, 4(3): 26.

Haraway, D. (1988). Situated knowledges: the science question in feminism and the privilege of partial perspective. Feminist Studies, 14(3): 575–99.

Harnan, S. , Tappenden, P. , Cooper, K. , Stevens, J. , Bessey, A. , Rafia, R. , Ward, S. , Wong, R. , Stein, R. , and Brown, J. (2017). Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10). Technology Assessment Report: Final report to the National Institute for Health and Care Excellence. Manchester: National Institute for Health and Care Excellence.

Harrison, C. J. , Spencer, R. G. , and Shackley, D. C. (2019). Transforming cancer outcomes in England: earlier and faster diagnoses, pathways to success, and empowering alliances. Journal of Healthcare Leadership, 11: 1–11.

Haslem, D. S. , Chakravarty, I. , Fulde, G. , Gilbert, H. , Tudor, B. P. , Lin, K. , Ford, J. M. , and Nadauld, L. D. (2018). Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs. Oncotarget, 9(15): 12316–22.

Hayden, C. (2007). Taking as giving: bioscience, exchange, and the politics of benefit-sharing. Social Studies of Science, 37(5): 729–58.

Hedgecoe, A. (2004). The politics of personalised medicine: pharmacogenetics in the clinic. Cambridge: Cambridge University Press.

Hedgecoe, A. (2005). ‘At the point at which you can do something about it, then it becomes more relevant’: informed consent in the pharmacogenetic clinic. Social Science & Medicine, 61(6): 1201–10.

Hedgecoe, A. , and Martin, P. (2003). The drugs don't work: expectations and the shaping of pharmacogenetics. Social Studies of Science, 33(3): 327–64.

Hiley, C. T. , Le Quesne, J. , Santis, G. , Sharpe, R. , De Castro, D. G. , Middleton, G. , and Swanton, C. (2016). Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. The Lancet, 388: 1002–11.

Hilgartner, S. (2017). Reordering life: knowledge and control in the genomics revolution. Cambridge, MA: MIT Press.

Hockings, E. (2014). Why we should opt out of the government's new patient database. The Guardian, 31 January, https://www.theguardian.com/science/political-science/2014/jan/31/why-we-should-opt-out-of-the-governments-new-patient-database (accessed 20 June 2020).

Hogarth, S. , and Saukko, P. (2017). A market in the making: the past, present and future of direct-to-consumer genomics. New Genetics and Society, 36(3): 197–208.

Hood, L. , and Auffray, C. (2013). Participatory medicine: a driving force for revolutionizing healthcare. Genome Medicine, 5: article no. 110.

Hood, L. , and Friend, S. H. (2011). Predictive, personalized, preventive, participatory (P4) cancer medicine. Nature Reviews Clinical Oncology, 8(3): 184–7.

Horlick-Jones, T. (2011). Understanding fear of cancer recurrence in terms of damage to ‘everyday health competence’. Sociology of Health & Illness, 33(6): 884–98.

Horst, M. , and Irwin, A. (2010). Nations at ease with radical knowledge: on consensus, consensusing and false consensusness. Social Studies of Science, 40(1): 105–26.

Hubbard, G. , Kidd, L. , and Kearney, N. (2010). Disrupted lives and threats to identity: the experiences of people with colorectal cancer within the first year following diagnosis. Health, 14(2): 131–46.

Human Genomics Strategy Group (2012). Building on our inheritance: genomic technology in healthcare. London: Department of Health.

Interlandi, J. (2016). The paradox of precision medicine. Scientific American, 314(4): 24–5.

Jain, L. S. (2007). Living in prognosis: toward an elegiac politics. Representations, 98(1): 77–92.

Jain, L. S. (2013). Malignant: how cancer becomes us. Berkeley, CA: University of California Press.

James, N. (1992). Care = organisation + physical labour + emotional labour. Sociology of Health & Illness, 14(4): 488–509.

Jasanoff, S. (2015). Future imperfect: science, technology, and the imaginations of modernity. In S. Jasanoff and S-H. Kim (eds), Dreamscapes of modernity: sociotechnical imaginaries and the fabrication of power, 1–33. Chicago: University of Chicago Press.

Jasen, P. (2009). From the ‘silent killer’ to the ‘whispering disease’: ovarian cancer and the uses of metaphor. Medical History, 53(4): 489–512.

Jerolmack, C. , and Tavory, I. (2014). Molds and totems: nonhumans and the constitution of the social self. Sociological Theory, 32(1): 64–77.

Joh, J. E. , Esposito, N. N. , Kiluk, J. V. , Laronga, C. , Lee, M. C. , Loftus, L. , Soliman, H. , Boughey, J. C. , Reynolds, C. , Lawton, T. J. , Acs, P. I. , Gordan, L. , and Acs, G. (2011). The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. The Oncologist, 16(11): 1520–6.

Kaiser, K. (2008). The meaning of the survivor identity for women with breast cancer. Social Science & Medicine, 67: 79–87.

Kaufman, S. R. (2015). Ordinary medicine: extraordinary treatments, longer lives, and where to draw the line. Durham, NC: Duke University Press.

Keating, P. , and Cambrosio, A. (2011). Cancer on trial: oncology as a new style of practice. Chicago: University of Chicago Press.

Kerr, A. , Swallow, J. , Chekar, C. K. , and Cunningham-Burley, S. (2019). Genomic research and the cancer clinic: uncertainty and expectations in professional accounts. New Genetics and Society, 38(2): 222–39.

Klawiter, M. (2004). Breast cancer in two regimes: the impact of social movements on illness experience. Sociology of Health & Illness, 26(6): 845–74.

Kohli-Laven, N. , Bourret, P. , Keating, P. , and Cambrosio, A. (2011). Cancer clinical trials in the era of genomic signatures: biomedical innovation, clinical utility, and regulatory-scientific hybrids. Social Studies of Science, 41(4): 487–513.

Lamprell, K. , Chin, M. , and Braithwaite, J. (2018). The plot thickens: archetypal narrative structure in the melanoma patient journey. Cogent Medicine, 5(1): 1484053. https://doi.org/10.1080/2331205X.2018.1484053 .

Landzelius, K. (2006). Introduction: patient organization movements and new metamorphoses in patienthood. Social Science & Medicine, 62(3): 529–37.

Largent, E. A. , Fernandez Lynch, H. , and McCoy, M. S. (2018). Patient-engaged research: choosing the ‘right’ patients to avoid pitfalls. Hastings Center Report, 48(5): 26–34.

Latimer, J. , Featherstone, K. , Atkinson, P. , Clarke, A. , Pilz, D. T. , and Shaw, A. (2006). Rebirthing the clinic: the interaction of clinical judgment and genetic technology in the production of medical science. Science, Technology, & Human Values, 31(5): 599–630.

Lewin, S. , and Reeves, S. (2011). Enacting ‘team’ and ‘teamwork’: using Goffman's theory of impression management to illuminate interprofessional practice on hospital wards. Social Science & Medicine, 72(10): 1595–602.

Lewis, S. , Willis, K. , Yee, J. , and Kilbreath, S. (2016). Living well? Strategies used by women living with metastatic breast cancer. Qualitative Health Research, 26(9): 1167–79.

Light, D. W. (2010). Bearing the risks of prescription drugs. In D. W. Light (ed.), The risks of prescription drugs, 1–39. New York: Columbia University Press.

Llewellyn, H. , Higgs, P. , Sampson, E. L. , Jones, L. , and Thorne, L. (2018). Topographies of ‘care pathways’ and ‘healthscapes’: reconsidering the multiple journeys of people with a brain tumour. Sociology of Health & Illness, 40(3): 410–25.

Loncaster, J. , Armstrong, A. , Howell, S. , Wilson, G. , Welch, R. , Chittalia, A. , Valentine, W. J. , and Bundred, N. J. (2017). Impact of Oncotype DX breast recurrence score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK. European Journal of Surgical Oncology, 43(5): 931–7.

Longo, D. L. (2013). Personalized cancer care is not new. The Oncologist, 18(6): 644–5.

Lupton, D. (2014). Digital sociology. Abingdon: Routledge.

MacKenzie, R. , Chapman, S. , Salkeld, G. , and Holding, S. (2008). Media influence on Herceptin subsidization in Australia: application of the rule of rescue? Journal of the Royal Society of Medicine, 101(6): 305–12.

Madden, M. , and Speed, E. (2017). Beware zombies and unicorns: toward critical patient and public involvement in health research in a neoliberal context. Frontiers in Sociology, 2: 7.

Madhu, N. (2017). Book review: Kaushik Sunder Rajan, Pharmocracy: Value, Politics, and Knowledge in Global Medicine. Sociological Bulletin, 66(3): 370–3.

Marcon, A. R. , Bieber, M. , and Caulfield, T. (2018). Representing a ‘revolution’: how the popular press has portrayed personalized medicine. Genetics in Medicine, 20(9): 950.

Marquart, J. , Chen, E. Y. , and Prasad, V. (2018). Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncology, 4(8): 1093–8.

Martin, P. (2018). Genomic hope: promise in the bioeconomy. In S. Gibbon, B. Prainsack, S. Hilgartner and J. Lamoreaux (eds), Routledge Handbook of Genomics, Health and Society, 79–89. Abingdon: Routledge.

Matthews-King, A. (2018). Most women with early stage breast cancer can avoid toxic chemotherapy, major trial finds. The Independent, 3 June, https://www.independent.co.uk/news/health/breast-cancer-chemotherapy-genetic-test-hormone-therapy-survival-a8380906.html (accessed 20 June 2020).

Maughan, T. (2017). The promise and the hype of ‘personalised medicine’. The New Bioethics, 23(1): 13–20.

McDonald, R. , Waring, J. , and Harrison, S. (2006). Rules, safety and the narrativisation of identity: a hospital operating theatre case study. Sociology of Health & Illness, 28(2): 178–202.

Mead, N. , and Bower, P. (2000). Patient-centredness: a conceptual framework and review of the empirical literature. Social Science & Medicine, 51(7): 1087–110.

Medical Research Council (2014). Clinical trials: why multi-arms are better than two. [online]. www.insight.mrc.ac.uk/2014/07/25/clinical-trials-why-multi-arms-are-better-than-two/ (accessed 30 August 2018).

Merletti, F. , Galassi, C. , and Spadea, T. (2011). The socioeconomic determinants of cancer. Environmental Health, 10(1): S7.

Metzler, I. (2010). Biomarkers and their consequences for the biomedical profession: a social science perspective. Personalized Medicine, 7(4): 407–20.

Michael, M. (2012). ‘What are we busy doing?’ Engaging the idiot. Science, Technology & Human Values, 37(5): 528–54.

Michael, M. (2017a). Enacting Big Futures, Little Futures: toward an ecology of futures. The Sociological Review, 65(3): 509–24.

Michael, M. (2017b). Futures of the present: from performativity to prehension. In N. Brown and B. Rappert (eds), Contested futures: a sociology of prospective techno-science, 21–39. Abingdon: Routledge.

Middleton, G. , Crack, L. R. , Popat, S. , Swanton, C. , Hollingsworth, S. J. , Buller, R. , Walker, I. , Carr, T. H. , Wherton, D. , and Billingham, L. J. (2015). The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Annals of Oncology, 26(12): 2464–9. https://doi.org/10.1093/annonc/mdv394 .

Miles, D. W. (2001). Update on HER-2 as a target for cancer therapy Herceptin in the clinical setting. Breast Cancer Research, 3: 380–4.

Miller, F. A. , Hayeems, R. Z. , Bytautas, J. P. , Bedard, P. L. , Ernst, S. , Hirte, H. , Hotte, S. , Oza, A. , Razak, A. , Welch, S. , and Winquist, E. (2014). Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. European Journal of Human Genetics, 22(3): 391.

Mitchell, R. , and Waldby, C. (2010). National biobanks: clinical labor, risk production, and the creation of biovalue. Science, Technology & Human Values, 35(3): 330–55.

Montgomery, C. M. (2017a). Clinical trials and the drive to material standardisation: ‘extending the rails’ or reinventing the wheel? Science and Technology Studies, 30(4): 30–44.

Montgomery, C. M. (2017b). From standardization to adaptation: clinical trials and the moral economy of anticipation. Science as Culture, 26(2): 232–54.

Moore, D. A. , Kushnir, M. , Mak, G. , Winter, H. , Curiel, T. , Voskoboynik, M. , and Forster, M. (2019). Prospective analysis of 895 patients on a UK genomics review board. ESMO Open, 4(2): e000469.

Moorhead, J. (2018). No chemo: the test that made me a lucky breast cancer patient. The Guardian, 4 June, https://www.theguardian.com/commentisfree/2018/jun/04/chemo-breast-cancer-oncotype-dx-test (accessed 20 June 2020).

Morange, M. (1997). From the regulatory vision of cancer to the oncogene paradigm, 1975–1985. Journal of the History of Biology, 30(1): 1–29.

Moreira, T. (2011). Health care rationing in an age of uncertainty: a conceptual model. Social Science & Medicine, 72(8): 1333–41.

Murphy, M. (2012). Seizing the means of reproduction: entanglements of feminism, health, and technoscience. Durham, NC: Duke University Press.

Murphy, M. (2015). Unsettling care: troubling transnational itineraries of care in feminist health practices. Social Studies of Science, 45(5): 717–37.

Murphy, E. , and Dingwall, R. (2007). Informed consent, anticipatory regulation and ethnographic practice. Social Science & Medicine, 65(11): 2223–34.

Nagaraj, G. , and Ma, C. X. (2013). Adjuvant chemotherapy decisions in clinical practice for early-stage node-negative, estrogen receptor-positive, HER2-negative breast cancer: challenges and considerations, Journal of the National Comprehensive Cancer Network, 11(3): 246–51.

Nahuis, R. , and Boon, W. P. C. (2011). The impact of patient advocacy: the case of innovative breast cancer drug reimbursement. Sociology of Health & Illness, 33(1): 1–15.

Nair, M. , Sandhu, S. S. , and Sharma, A. K. (2018). Cancer molecular markers: a guide to cancer detection and management. Seminars in Cancer Biology, 52: 39–55.

Nakagawa, H. , and Fujita, M. (2018). Whole genome sequencing analysis for cancer genomics and precision medicine. Cancer Science, 109(3): 513–22.

Nawrocki, S. (2018). Molecular profiling of tumours for precision oncology – high hopes versus reality. Contemporary Oncology, 22(1A): 3.

Nelson, N. C. , Keating, P. , and Cambrosio, A. (2013). On being ‘actionable’: clinical sequencing and the emerging contours of a regime of genomic medicine in oncology. New Genetics and Society, 32(4): 405–28.

NICE (National Institute for Health and Care Excellence) (2013). Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. Manchester: National Institute for Health and Care Excellence.

NICE (National Institute for Health and Care Excellence) (2017). Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10): Final Scope. Manchester: National Institute for Health and Care Excellence.

NICE (National Institute for Health and Care Excellence) (2018a). Diagnostics consultation document: tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Manchester: National Institute for Health and Care Excellence.

NICE (National Institute for Health and Care Excellence) (2018b). Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Manchester: National Institute for Health and Care Excellence.

NICE (National Institute for Health and Care Excellence) (2018c). Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: Diagnostics Consultation Document – Comments. Manchester: National Institute for Health and Care Excellence.

Novas, C. (2006). The political economy of hope: patients’ organizations, science and biovalue. BioSocieties, 1(3): 289–305.

Nussinov, R. , Hyunbum, J. , Tsai, C.-J. and Cheng, F. (2019). Precision medicine and driver mutations: computational methods, functional assays and conformational principles for interpreting cancer drivers. PLoS Computational Biology, 15(3): e1006658.

Olopade, O. I. , Grushko, T. A. , Nanda, R. and Huo, D. (2008). Advances in breast cancer: pathways to personalized medicine. Clinical Cancer Research, 14(24): 7988–99.

Orgad, S. (2005). The transformative potential of online communication: the case of breast cancer patients’ Internet spaces. Feminist Media Studies, 5(2): 141–61.

Parsons, E. , and Atkinson, P. (1992). Lay constructions of genetic risk. Sociology of Health & Illness, 14(4): 437–55.

Petersen, A. , and Lupton, D. (1997). The new public health: health and self in the age of risk. London: Sage.

Petersen, A. , Schermuly, A. C. , and Anderson, A. (2019). The shifting politics of patient activism: from bio-sociality to bio-digital citizenship. Health, 23(4): 478–94.

Powell, H. A. (2019). Socioeconomic deprivation and inequalities in lung cancer: time to delve deeper? Thorax, 74(1): 11–12.

Prainsack, B. (2017). Personalized medicine: empowered patients in the 21st century? New York: NYU Press.

Puig de La Bellacasa, M. P. (2011). Matters of care in technoscience: assembling neglected things. Social Studies of Science, 41(1): 85–106.

Puig de la Bellacasa, M. P. (2012). ‘Nothing comes without its world’: thinking with care. The Sociological Review, 60(2): 197–216.

Rabeharisoa, V. , Moreira, T. , and Akrich, M. (2014). Evidence-based activism: patients’, users’ and activists’ groups in Knowledge Society. Biosocieties, 9(2): 111–28.

Rajan, K. S. (2006). Biocapital: the constitution of postgenomic life. Durham, NC: Duke University Press.

Rapp, R. (1998). Refusing prenatal diagnosis: the meanings of bioscience in a multicultural world. Science, Technology, & Human Values, 23(1): 45–70.

Roberts, K. , and Clarke, C. (2009). Future disorientation following gynaecological cancer: women's conceptualisation of risk after a life-threatening illness. Health, Risk & Society, 11(4): 353–66.

Rose, N. (2001). The politics of life itself. Theory, Culture & Society, 18(6): 1–30.

Ross, E. , Swallow, J. , Kerr, A. , and Cunningham-Burley, S. (2019). Online accounts of gene expression profiling in early-stage breast cancer: interpreting genomic testing for chemotherapy decision making. Health Expectations, 22(1): 74–82.

Sample, I. (2014). PM: Genome project will transform cancer care. The Guardian, 1 August, www.theguardian.com/society/2014/aug/01/nhs-genetic-analysis-serious-diseases-diagnosed-treated (accessed 20 June 2020).

Samuel, G. N. , and Farsides, B. (2017). The UK's 100,000 Genomes Project: manifesting policymakers’ expectations. New Genetics and Society, 36(4): 336–53.

Schellekens, H. , Aldosari, M. , Talsma, H. , and Mastrobattista, E. (2017). Making individualized drugs a reality. Nature Biotechnology, 35(6): 507–13.

Scottish Scientific Advisory Council (2019). Informing the future of genomic medicine in Scotland. Edinburgh: Scottish Science Advisory Council.

Selin, C. (2008). The sociology of the future: tracing stories of technology and time. Sociology Compass, 2(6): 1878–95.

Shack, L. , Jordan, C. , Thomson, C. S. , Mak, V. , and Møller, H. (2008). Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in England. BMC Cancer, 8(1): 271.

Skloot, R. (2017). The immortal life of Henrietta Lacks. Portland, OR: Broadway Books.

Smyth, C. (2013). Test could spare women the ordeal of chemotherapy. The Times, 26 September, https://www.thetimes.co.uk/article/test-could-spare-women-the-ordeal-of-chemotherapy-b50tbbmmwf0 (accessed 20 June 2020).

Sparano, J. A. , Gray, R. J. , Makower, D. F. , et al. (2018). Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. New England Journal of Medicine, 379: 111–21.

Stage, C. (2017). Networked cancer: affect, narrative and measurement. Basingstoke: Palgrave Macmillan.

Star, S. L. (1985). Scientific work and uncertainty. Social Studies of Science, 15(3): 391–427.

Steinberg, D. L. (2015). The bad patient: estranged subjects of the cancer culture. Body & Society, 21(3): 115–43.

Suchman, L. (1996). Supporting articulation work. In R. Kling (ed.), Computerization and controversy: value conflicts and social choices, 407–23. London: Academic Press.

Sulik, G. (2009). Managing biomedical uncertainty: the technoscientific illness identity. Sociology of Health & Illness, 30(7): 1059–76.

Sulik, G. (2014). #Rethinkpink: moving beyond Breast Cancer Awareness SWS Distinguished Feminist Lecture. Gender & Society, 28(5): 655–78.

Swallow, J. (2019). Constructing classification boundaries in the memory clinic: negotiating risk and uncertainty in constituting mild cognitive impairment. Sociology of Health & Illness [online only/early view], 14 November 2019. https://doi.org/10.1111/1467-9566.1301 .

Swallow, J. , Kerr, A. , Chekar, C. K. , and Cunningham-Burley, S. (2020). Accomplishing an adaptive clinical trial for cancer: valuation practices and care work across the laboratory and the clinic. Social Science & Medicine, 252: 112949. https://doi.org/10.1016/j.socscimed.2020.112949

TallBear, K. (2013). Native American DNA: tribal belonging and the false promise of genetic science. Minneapolis, MN: University of Minnesota Press.

Tarkkala, H. , Helén, I. , and Snell, K. (2019). From health to wealth: the future of personalized medicine in the making. Futures, 109: 142–52.

Timmermans, S. (2005). From autonomy to accountability: the role of clinical practice guidelines in professional power. Perspectives in Biology and Medicine, 48(4): 490–501.

Tiriveedhi, V. (2018). Impact of precision medicine on drug repositioning and pricing: a too small to thrive crisis. Journal of Personalized Medicine, 8(4): 36. doi:10.3390/jpm8040036 .

Tronto, J. C. (1993). Moral boundaries: a political argument for an ethic of care. London: Routledge.

Tupasela, A. (2017). Populations as brands in medical research: placing genes on the global genetic atlas. BioSocieties, 12(1): 47–65.

Tutton, R. (2012). Personalizing medicine: futures present and past. Social Science & Medicine, 75(10): 1721–8.

Tutton, R. , and Jamie, K. (2013). Personalized medicine in context: social science perspectives. Drug Discovery Today: Therapeutic Strategies, 10(4): e183–e187.

Twigg, J. , Wolkowitz, C. , Cohen, R. L. , and Nettleton, S. (2011). Conceptualising body work in health and social care. Sociology of Health & Illness, 33(2): 171–88.

Van Dijck, J. , and Poell, T. (2013). Understanding social media logic. Media and Communication, 1(1): 2–14.

van Helvoort, T. (1999). A century of research into the cause of cancer: is the new oncogene paradigm revolutionary? History and Philosophy of the Life Sciences, 21(3): 293–330.

Van Lente, H. , and Rip, A. (1998). The rise of membrane technology: from rhetorics to social reality. Social Studies of Science, 28(2): 221–54.

Vasella, D. , and Slater, R. (2003). Magic cancer bullet: how a tiny orange pill is rewriting medical history. New York: Harper Business.

Vicari, S. , and Cappai, F. (2016). Health activism and the logic of connective action: a case study of rare disease patient organisations. Information, Communication & Society, 19(11): 1653–71.

Ward, E. , Jemal, A. , Cokkinides, V. , Singh, G. K. , Cardinez, C. , Ghafoor, A. , and Thun, M. (2004). Cancer disparities by race/ethnicity and socioeconomic status. CA: A Cancer Journal for Clinicians, 54(2): 78–93.

Wenger, M. L. , and Oliffe, L. J. (2014). Men managing cancer: a gender analysis. Sociology of Health & Illness, 36(1): 108–22.

West, H. J. (2017). Novel precision medicine trial designs umbrellas and baskets. JAMA Oncology Patient, 3(3): 423. doi:10.1001/jamaoncol.2016.5299 .

Will, C. , and Moreira, T. (2010). Medical proofs, social experiments. In C. Will and T. Moreira (eds), Clinical trials in shifting contexts. Aldershot: Ashgate.

Williams, S. J. , Martin, P. , and Gabe, J. (2011). The pharmaceuticalisation of society? A framework for analysis. Sociology of Health & Illness, 33(5): 710–25.

Yan, S. (2017). Prostate cancer patienthood in the genomic era: a study of patients’ online accounts. Master of Public Health dissertation, University of Edinburgh.

Yeo, S. K. , and Guan J.-L. (2017). Breast cancer: multiple subtypes within a tumor? Trends in Cancer, 3(1): 753–60.

Zafar, S. Y. (2015). Financial toxicity of cancer care: it's time to intervene. Journal of the National Cancer Institute, 108(5): djv370. doi:10.1093/jnci/djv370 .

Ziebland, S. , and Wyke, S. (2012). Health and illness in a connected world: how might sharing experiences on the internet affect people's health? The Milbank Quarterly, 90(2): 219–49.

Zuboff, S. (2019). The age of surveillance capitalism: the fight for a human future at the new frontier of power. London: Profile Books.

Personalised cancer medicine

Future crafting in the genomic era

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 110 110 8
PDF Downloads 73 73 8